Target intelligence / Profile preview

Rotavirus outer-layer protein VP7 and spike protein VP4 (VP7 and VP4 (rotavirus))

Target
VP7 and VP4 (rotavirus)
Molecular classification
Viral structural protein, Glycoprotein (VP7), Spike protein (VP4), Capsid protein
01

Overview

Rotavirus is a major cause of severe diarrhea in infants and young children. Its virion consists of a triple-layered icosahedral capsid; the outermost layer is formed by VP7, a calcium-stabilized glycoprotein arranged in trimers, and VP4, an unglycosylated spike protein that projects out from the VP7 layer[6][1][3]. VP4 mediates viral attachment to host cells and entry by mediating endosomal membrane penetration, while VP7 is involved in assembly, virion stability, and is a principal target of protective antibodies[1][2][3][6][7]. Both proteins elicit neutralizing antibody responses and are thus integral vaccine antigens and therapeutic targets[5][7][8]. The genetic and antigenic properties of VP7 and VP4 are used to define rotavirus G and P serotypes, essential for epidemiological tracking and vaccine design[4][8]. Diverse genotypes of VP7 and VP4 contribute to immune escape and continued disease burden, highlighting their centrality in rotavirus pathobiology and prevention strategies[5][8][9].

Other names
VP7 glycoproteinVP4 spike proteinRotavirus neutralization proteinsG serotype protein (VP7)P serotype protein (VP4)
02

Mechanism of action

Neutralizing antibodies block cell attachment and entry (VP4 & VP7) Inhibition of conformational transitions required for viral penetration (VP4) Preventing uncoating and release of viral genome (VP7)

03

Biological functions

Virus cell attachment (VP4)Virus entry and membrane penetration (VP4)Immune evasion (VP7, VP4)Virion assembly and maturation (VP7)Induction of neutralizing antibody response (VP7, VP4)Host range and virulence modulation (VP4)
04

Disease associations

Infection (rotavirus gastroenteritis)Other (pediatric diarrheal disease)
05

Safety considerations

Antigenic diversity of VP7 and VP4 leads to challenges in vaccine breadth and efficacyAntigenic drift and shifts (G and P genotypes) can allow escape from immunity induced by current vaccinesRare risk of vaccine-associated intussusception (for live rotavirus vaccines targeting these proteins; relates to overall vaccine, not direct protein effect)
06

Interacting drugs

Rotavirus vaccines (live-attenuated, e.g., Rotarix, RotaTeq; these induce antibody responses targeting VP4 and VP7)
07

Biomarkers

Serum neutralizing antibody titers against VP4 and VP7Determination of G and P serotypes for rotavirus

Beyond the preview

Go deeper on Rotavirus outer-layer protein VP7 and spike protein VP4 (VP7 and VP4 (rotavirus)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rotavirus outer-layer protein VP7 and spike protein VP4 (VP7 and VP4 (rotavirus)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call